Dual Protection Therapy with Staged Coronary Artery Bypass Surgery and Stenting in Patients with Left Main Coronary Artery Stenosis: Long-Term Results from a Single Center

Authors

  • I-Chang Hsieh
  • Pyng-Jing Lin
  • Shang-Hung Chang
  • Ming-Jer Hsieh
  • Fen-Chiung Lin
  • Delon Wu
  • Chun-Chi Chen

DOI:

https://doi.org/10.1532/HSF98.2013282

Abstract

Objective: We evaluated the efficacy and safety of dual protection therapy with staged coronary artery bypass grafting (CABG) and bare-metal stenting (BMS) in patients with left main coronary artery (LMCA) disease.

Background: CABG is currently the preferred therapy for complex LMCA disease; however, the long-term patency rates of these grafts are unsatisfactory, and stenting alone for LMCA may be associated with the potentially fatal consequences of stent thrombosis or restenosis.

Methods: Between January 1997 and October 2005, 42 patients underwent staged bypass surgery and BMS, with the latter procedure performed 2 weeks after the initial CABG. Of these patients, 40 received left internal mammary artery (LIMA) grafts, 34 saphenous vein grafts, 6 radial artery grafts, and 3 right IMA (RIMA) grafts. Minimally invasive bypass surgery was performed in 10 patients.

Results: There were no operative complications. Forty-two stents were implanted in 42 lesions without complications. During the follow-up period of 135 ± 55 months, 1 patient died of cancer, 2 of cardiac causes, and 5 patients (12%) experienced target lesion revascularization. The target vessel failure rate was 24%. Forty patients (95%) underwent a 6-month angiographic follow-up. Restenosis was noted in 7 patients (18%). Reocclusion was also noted in 5 LIMA grafts, 5 saphenous vein grafts, 1 radial artery graft, and 1 RIMA graft. Only 1 patient experienced both restenosis of LM stenting and total occlusion of the 2 bypass grafts.

Conclusions: Dual protection therapy with staged CABG and stenting is not an appropriate therapeutic strategy because of unacceptable graft patency rate. A higher occlusive rate of the bypass grafts may result from decreased blood flow because of competing blood flow between the bypass graft and the native coronary vessel.

References

Barner HB, Standeven JW, Reese J. 1985. Twelve-year experience with internal mammary artery for coronary artery bypass. J Thorac Cardiovasc Surg 90:668-75.nBlack A, Cortina R, Bossi I, Choussat R, Fajadet J, Marco J. 2001. Unprotected left main coronary artery stenting: correlates of midterm survival and impact of patient selection. J Am Coll Cardiol 37:832-8.nBonatti J, Lehr E, Vesely MR, Friedrich G, Bonaros N, Zimrin D. 2010. Hybrid coronary revascularization: which patients? When? How? Curr Opin Cardiol 25:568-74.nBourassa MG, Enjalbert M, Campeau L, Lesperance J. 1984. Progression of atherosclerosis in coronary arteries and bypass grafts: ten years later. Am J Cardiol 53:102C-7C.nBourassa MG. 1981. Long-term vein graft patency. Curr Opin Cardiol 9:685-91nChaitman BR, Fisher LD, Bourassa MG, et al. 1981. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am J Cardiol 48:765-77.nCaracciolo EA, Davis KB, Sopko G, et al. 1995. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term cass experience. Circulation 91:2325-34.nChechi T, Vecchio S, Vittori G, et al. 2008. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 51:2396-402.nChieffo A, Stankovic G, Bonizzoni E, et al. 2005. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 111:791-5.nCohen MV, Gorlin R. 1975. Main left coronary artery disease. Clinical experience from 1964-1974. Circulation 52:275-85.nCutlip DE, Baim DS, Ho KK, et al. 2001. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 103:1967-71.nEllis SG, Hill CM, Lytle BW. 1998. Spectrum of surgical risk for left main coronary stenoses: benchmark for potentially competing percutaneous therapies. Am Heart J 135 (2 Pt 1):335-8.nEllis SG, Tamai H, Nobuyoshi M, et al. 1997. Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996. Circulation 96:3867-72.nHerrick JB. 1983. Landmark article (JAMA 1912). Clinical features of sudden obstruction of the coronary arteries. JAMA 250:1757-65.nKim YH, Park DW, Lee SW, et al. 2009. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 120:400-7.nLin PJ, Chang CH, Chu JJ, et al. 1998. Minimal access surgical techniques in coronary artery bypass grafting for triple-vessel disease. Ann Thorac Surg 65:407-12.nMorice MC, Serruys PW, Sousa JE, et al. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-80.nPark DW, Seung KB, Kim YH, et al. 2010. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol 56:117-24.nPark SJ, Kim YH, Lee BK, et al. 2005. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 45:351-6.nPark SJ, Park SW, Hong MK, et al. 2003. Long-term (three-year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Am J Cardiol 91:12-6.nPark SJ, Park SW, Hong MK, et al. 1998. Stenting of unprotected left main coronary artery stenoses: immediate and late outcomes. J Am Coll Cardiol 31:37-42.nPrice MJ, Cristea E, Sawhney N, et al. 2006. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol 47:871-7.nSabik JF 3rd, Blackstone EH. 2008. Coronary artery bypass graft patency and competitive flow. J Am Coll Cardiol 51:126-8.nSabik JF 3rd, Lytle BW, Blackstone EH, Khan M, Houghtaling PL, Cosgrove DM. 2003. Does competitive flow reduce internal thoracic artery graft patency? Ann Thorac Surg 76:1490-6.nSerruys PW, Morice MC, Kappetein AP, et al. 2009. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360:961-72.nShimizu T, Hirayama T, Suesada H, Ikeda K, Ito S, Ishimaru S. 2000. Effect of flow competition on internal thoracic artery graft: postoperative velocimetric and angiographic study. J Thorac Cardiovasc Surg 120:459-65.nSianos G, Morel MA, Kappetein AP, et al. 2005. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1:219-27.nSilvestri M, Barragan P, Sainsous J, et al. 2000. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 35:1543-50.nSuarez de Lezo J, Medina A, Romero M, et al. 2001. Predictors of restenosis following unprotected left main coronary stenting. Am J Cardiol 88:308-10.nTakaro T, Hultgren HN, Lipton MJ, et al. 1976. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circulation 54 (6 Suppl):III107-17.nTan WA, Tamai H, Park SJ, et al. 2001. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation 104:1609-14.nValgimigli M, Malagutti P, Rodriguez-Granillo GA, et al. 2006. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol 47:1530-7.nValgimigli M, van Mieghem CA, Ong AT, et al. 2005. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 111:1383-9.nVeterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. 1984. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med 311:1333-9.n

Published

2014-03-14

How to Cite

Hsieh, I.-C., Lin, P.-J., Chang, S.-H., Hsieh, M.-J., Lin, F.-C., Wu, D., & Chen, C.-C. (2014). Dual Protection Therapy with Staged Coronary Artery Bypass Surgery and Stenting in Patients with Left Main Coronary Artery Stenosis: Long-Term Results from a Single Center. The Heart Surgery Forum, 17(1), E47-E53. https://doi.org/10.1532/HSF98.2013282

Issue

Section

Articles

Most read articles by the same author(s)